American Journal of Kidney Diseases
Volume 50, Issue 3 , Pages 354-357 , September 2007

Dialysis Facility Ownership and Epoetin Dosing in Hemodialysis Patients: A US Physician Perspective

  • Bertram L. Kasiske, MD

      Affiliations

    • Corresponding Author InformationAddress correspondence to Bertram L. Kasiske, MD, Department of Medicine, Hennepin County Medical Center, 701 Park Ave, Minneapolis, MN 55415.

References 

  1. Suzuki M, Hirasawa Y, Hirashima K, et al. Dose-finding, double-blind, clinical trial of recombinant human erythropoietin (Chugai) in Japanese patients with end-stage renal disease (Research Group for Clinical Assessment of rhEPO). Contrib Nephrol. 1989;76:179–192
  2. Bahlmann J, Schoter KH, Scigalla P, et al. Morbidity and mortality in hemodialysis patients with and without erythropoietin treatment: a controlled study. Contrib Nephrol. 1991;88:90–106
  3. Laupacis A. A randomized double-blind study of recombinant human erythropoietin in anaemic hemodialysis patients (Canadian Erythropoietin Study Group). Transplant Proc. 1991;23:1825–1826
  4. Sikole A, Polenakovic M, Spirovska V, Polenakovic B, Masin G. Analysis of heart morphology and function following erythropoietin treatment of anemic dialysis patients. Artif Organs. 1993;17:977–984
  5. Besarab A, Bolton WK, Browne JK, et al. The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin. N Engl J Med. 1998;339:584–590
  6. Foley RN, Parfrey PS, Morgan J, et al. Effect of hemoglobin levels in hemodialysis patients with asymptomatic cardiomyopathy. Kidney Int. 2000;58:1325–1335
  7. Furuland H, Linde T, Ahlmen J, Christensson A, Strombom U, Danielson BG. A randomized controlled trial of haemoglobin normalization with epoetin alfa in pre-dialysis and dialysis patients. Nephrol Dial Transplant. 2003;18:353–361
  8. Parfrey PS, Foley RN, Wittreich BH, Sullivan DJ, Zagari MJ, Frei D. Double-blind comparison of full and partial anemia correction in incident hemodialysis patients without symptomatic heart disease. J Am Soc Nephrol. 2005;16:2180–2189
  9. National Kidney Foundation. NKF-DOQI clinical practice guidelines for the treatment of anemia of chronic renal failure. Am J Kidney Dis. 1997;30(suppl 3):S192–S240
  10. Berns JS, Elzein H, Lynn RI, Fishbane S, Meisels IS, Deoreo PB. Hemoglobin variability in epoetin-treated hemodialysis patients. Kidney Int. 2003;64:1514–1521
  11. Lacson E, Ofsthun N, Lazarus JM. Effect of variability in anemia management on hemoglobin outcomes in ESRD. Am J Kidney Dis. 2003;41:111–124
  12. Thamer M, Zhang Y, Kaufman J, Stefanik K, Cotter DJ. Factors influencing route of administration for epoetin treatment among hemodialysis patients in the United States. Am J Kidney Dis. 2006;48:77–87
  13. Collins AJ, Ebben JP, Gilbertson DT. EPO adjustments in patients with elevated hemoglobin levels: provider practice patterns compared with recommended practice guidelines. Am J Kidney Dis. 2007;49:135–142
  14. United States Renal Data System. USRDS 2006 Annual Data Report: Atlas of End-Stage Renal Disease in the United States. In: Bethesda, MD: National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases; 2007;p. 191–204
  15. Thamer M, Zhang Y, Kaufman J, Cotter D, Dong F, Hernan MA. Dialysis facility ownership and epoetin dosing in patients receiving hemodialysis. JAMA. 2007;297:1667–1674
  16. Drueke TB, Locatelli F, Clyne N, et al. Normalization of hemoglobin level in patients with chronic kidney disease and anemia. N Engl J Med. 2006;355:2071–2084
  17. Singh AK, Szczech L, Tang KL, et al. Correction of anemia with epoetin alfa in chronic kidney disease. N Engl J Med. 2006;355:2085–2098
  18. Phrommintikul A, Haas SJ, Elsik M, et al. Mortality and target haemoglobin concentrations in anaemic patients with chronic kidney disease treated with erythropoietin: a meta-analysis. Lancet. 2007;369:381–388
  19. US Food and Drug Administration and Center for Drug Evaluation and Research. Information for Healthcare Professionals: Erythropoiesis Stimulating Agents (ESA). http://www.fda.gov/cder/drug/infopage/RHE/default.htm. Accessed June 14, 2007
  20. Coyne DW. Use of epoetin in chronic renal failure. JAMA. 2007;297:1713–1716

PII: S0272-6386(07)01032-3

doi: 10.1053/j.ajkd.2007.07.002

American Journal of Kidney Diseases
Volume 50, Issue 3 , Pages 354-357 , September 2007

Article Tools